{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:57:51Z","timestamp":1791075471438,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,15]]},"abstract":"<jats:p>Between February 1996 and December 2004, the German Leukemia Study Initiative registered 1766 consecutive patients for the acute myeloid leukemia (AML) 96 study, all of whom were diagnosed by central cytomorphology according to the French-American-British (FAB) and the new World Health Organization (WHO) classification. We focused our analysis on the prognostic impact of multilineage dysplasia (MLD) as a new parameter of the WHO classification for AML. We could not confirm the WHO statement that MLD occurs most frequently in older individuals, but we confirmed that MLD is often associated with an unfavorable cytogenetic profile (P &lt; .001). In 1332 individuals receiving intensive AML therapy presence of MLD was negatively correlated with complete remission (P = .001) in univariate, but not in multivariate, analysis. Multivariate analysis of either event-free or overall survival again failed to show an independent prognostic significance of MLD besides age, cytogenetics, and, in part, NPM1\/FLT3-ITD mutations. Our data support a reassessment of the WHO classification in the light of a more biologic understanding of AML. This study is registered at www.ClinicalTrials.gov as #NCT00180115.<\/jats:p>","DOI":"10.1182\/blood-2007-08-101162","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T02:56:38Z","timestamp":1196823398000},"page":"1855-1861","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients"],"prefix":"10.1182","volume":"111","author":[{"given":"Hannes","family":"Wandt","sequence":"first","affiliation":[{"name":"Klinikum N\u00fcrnberg, Medizinische Klinik 5, H\u00e4matologie\/Onkologie, N\u00fcrnberg;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Sch\u00e4kel","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Prange-Krex","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Mohr","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pascheberg","sequence":"additional","affiliation":[{"name":"Zytogenetisches Labor Dr Eberhard u. Partner, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Soucek","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schaich","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus der Technischen Universit\u00e4t Dresden, Medizinische Klinik u. Poliklinik I, Dresden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111817584222200_B1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) Cooperative Group.","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposal for the classification of myelodysplastic syndromes.","volume":"51","author":"Bennet","year":"1982","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group.","volume":"103","author":"Bett","year":"1985","journal-title":"Ann Intern Med"},{"key":"2019111817584222200_B4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.7326\/0003-4819-103-3-460","article-title":"Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7).","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"2019111817584222200_B5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.1991.tb04444.x","article-title":"Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0).","volume":"78","author":"Bennett","year":"1991","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.1987.tb01325.x","article-title":"Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia.","volume":"66","author":"Brito-Babapulle","year":"1987","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B7","first-page":"520","article-title":"Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.","volume":"6","author":"Goasguen","year":"1992","journal-title":"Leukemia"},{"key":"2019111817584222200_B8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002770050320","article-title":"Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia.","volume":"75","author":"Kahl","year":"1997","journal-title":"Ann Hematol"},{"key":"2019111817584222200_B9","first-page":"946","article-title":"De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.","volume":"10","author":"Gahn","year":"1996","journal-title":"Leukemia"},{"key":"2019111817584222200_B10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2257.1990.tb01111.x","article-title":"Prognostic value of dysmyelopoietic features in de novo acute myeloid leukemia: a report on 132 patients.","volume":"12","author":"Estienne","year":"1990","journal-title":"Clin Lab Haematol"},{"key":"2019111817584222200_B11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2141.1987.tb01328.x","article-title":"Dysmegakaryocytopoiesis in acute leukemias: its predominance in myelomonocytic (M4) leukaemia and implication for response to chemotherapy.","volume":"66","author":"Jinnai","year":"1987","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2141.1994.tb04827.x","article-title":"Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia.","volume":"86","author":"Kuriyama","year":"1994","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02981909","article-title":"Morphological diagnoses of the Japan Adult Leukemia Study Group acute myeloid leukemia protocols: Central Review.","volume":"73","author":"Kuriyama","year":"2001","journal-title":"Int J Hematol"},{"key":"2019111817584222200_B14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1309\/EM7KCQR4GLMHRCX4","article-title":"Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival.","volume":"119","author":"Arber","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"2019111817584222200_B15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1097-0142(19940115)73:2<314::AID-CNCR2820730214>3.0.CO;2-C","article-title":"Bone marrow dyplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival.","volume":"73","author":"Ballen","year":"1994","journal-title":"Cancer"},{"key":"2019111817584222200_B16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2003.08.005","article-title":"Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.","volume":"21","author":"Haferlach","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111817584222200_B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2141.2003.03981.x","article-title":"Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia.","volume":"120","author":"Miyazaki","year":"2003","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B18","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: Report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997.","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111817584222200_B19","first-page":"75","article-title":"Acute myeloid leukemia.","volume-title":"World Health Organisation of Tumours, Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues","author":"Brunning","year":"2001"},{"key":"2019111817584222200_B20","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"Prerequisites for the diagnosis of myeloid neoplasms by the WHO classification.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019111817584222200_B21","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial.","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"2019111817584222200_B22","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"2019111817584222200_B23","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"2019111817584222200_B24","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"2019111817584222200_B25","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2004.03.023","article-title":"Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461.","volume":"22","author":"Marcucci","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111817584222200_B26","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"2019111817584222200_B27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111817584222200_B28","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"2019111817584222200_B29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","article-title":"Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?","volume":"109","author":"Mr\u00f3zek","year":"2007","journal-title":"Blood"},{"key":"2019111817584222200_B30","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group.","volume":"94","author":"Fenaux","year":"1999","journal-title":"Blood"},{"key":"2019111817584222200_B31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1365-2141.2001.02562.x","article-title":"Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.","volume":"112","author":"Schaich","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111817584222200_B32","volume-title":"ISCN 2005, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature","author":"Shaffer","year":"2005"},{"key":"2019111817584222200_B33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"key":"2019111817584222200_B34","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111817584222200_B35","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia.","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"2019111817584222200_B36","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.","volume":"89","author":"Leith","year":"1989","journal-title":"Blood"},{"key":"2019111817584222200_B37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"key":"2019111817584222200_B38","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","article-title":"Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medial Research Council's 10th AML Trial (MRC AML10).","volume":"89","author":"Hann","journal-title":"Blood"},{"key":"2019111817584222200_B39","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2004.11.106","article-title":"Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of cancer and leukemia Group B Study 9621.","volume":"22","author":"Kolitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111817584222200_B40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia.","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"2019111817584222200_B41","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood.V85.10.2643.bloodjournal85102643","article-title":"All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.","volume":"85","author":"Degos","year":"1995","journal-title":"Blood"},{"key":"2019111817584222200_B42","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111817584222200_B43","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2004-12-4938","article-title":"Diagnosis of leukemia by gene expression profiling.","volume":"106","author":"Haferlach","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/4\/1855\/1221276\/zh800408001855.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/4\/1855\/1221276\/zh800408001855.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T04:25:14Z","timestamp":1588134314000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/4\/1855\/133307\/MLD-according-to-the-WHO-classification-in-AML-has"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,15]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-08-101162","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,15]]}}}